Fisher Asset Management LLC Acquires 127,228 Shares of Bristol-Myers Squibb (NYSE:BMY)

Fisher Asset Management LLC increased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 130.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,537 shares of the biopharmaceutical company’s stock after acquiring an additional 127,228 shares during the quarter. Fisher Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $11,521,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at about $25,000. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at about $27,000. Blue Bell Private Wealth Management LLC increased its stake in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at about $40,000. Finally, Wetzel Investment Advisors Inc. bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at about $40,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

BMY stock opened at $43.90 on Tuesday. The business has a 50 day moving average price of $50.24 and a 200 day moving average price of $50.57. The stock has a market cap of $88.99 billion, a price-to-earnings ratio of -14.16, a PEG ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a fifty-two week low of $43.33 and a fifty-two week high of $69.10. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the previous year, the business earned $2.05 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.47%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analysts Set New Price Targets

A number of research firms have weighed in on BMY. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Barclays dropped their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.